A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

计划入组 160 人 · 首次发布于 2025 年 6 月 17 日

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

计划入组 466 人 · 首次发布于 2025 年 10 月 9 日

Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1

计划入组 590 人 · 首次发布于 2026 年 9 月 1 日

CDK2-Cyclin E Precision Therapeutic

Cyclin D1 degraders (cancer)

CDK2/cyclin A inhibitors (Genentech)

Dong-E-E-Jiao Co.,Ltd.

China

BIOLOGICAL E. LIMITED

India

Biological E Limited.

United States

Aprea Therapeutics Advances WEE1 and ATR Inhibitors in Clinical Trials

Circle Pharma Nominates CID-165 as Second Oncology Program Targeting Cyclin D1-Driven Cancers

Biotheryx Completes Enrollment in Phase 1a Trial of First-in-Class CDK4/6 Degrader BTX-9341 for HR+/HER2- Breast Cancer